Organic Active Ingredients TRIZ Cases

Defined crystalline tryptamine salts improve molecular weight determination and dosing precision while reducing concentration calculation errors.

Genetically edited iPSC-derived effector cells use Fas redirector and CAR mechanisms to resist apoptosis and improve tumor targeting.

Steroids given after anti-VEGF treatment help manage refractory retinal conditions while reducing inflammation and supporting vascular health.

Amphiphilic and hydrophobic additives help in situ implants carry more drug while extending release from weeks to months.

A 19-nor pyrazolyl steroid increases non-REM and slow wave sleep while preserving REM patterns and reducing wakefulness after sleep onset.

An oral ponesimod up-titration and maintenance regimen treats relapsing and active progressive MS while reducing relapses, lesions, and fatigue.

A pre-injection dispersion step reverses aripiprazole gelation to restore homogeneity and lower injection resistance after storage.

Nanomolar pyridonopyrimidine RSK inhibitors address the lack of selective Ras-MAPK pathway drugs for targeted cancer treatment.

Dose adjustment of MATE1 or OCT2 substrates with levoketoconazole helps lower cortisol while limiting hepatotoxicity and drug interactions.

Substituted gamma-carbolines balance serotonin, dopamine, and mu-opioid activity to treat OCD and OUD with lower side effects and addiction risk.

By altering red blood cell permeability and tracking osmotic parameters, this case shows a route to malaria resistance and susceptibility assessment.

Alternating TTFields paired with adaptive ultra-fractionated radiotherapy improve tumor killing while allowing personalized timing and lower normal tissue toxicity.

Multiple crystalline, amorphous, hydrate, and solvate PKC inhibitor forms improve stability and bioavailability for pharmaceutical dosing.

Bivalent compounds link a TRK ligand to an E3 ligase tag to degrade TRK proteins, mutants, and fusions with higher specificity.

Targeted oxysterol substitutions improve NMDA receptor potency, oral bioavailability, stability, and safety for CNS and metabolic disorders.

Activating growth factor receptors while inhibiting adhesion proteins reverts neoplastic cells without destructive chemotherapy or gene integration.

Blocking XPO1-mediated nuclear export helps myxoma virus replicate in nonpermissive tumor cells, improving cancer cell killing and reducing metastasis.

Targeting sGC signaling raises cGMP to improve endothelial function, reduce inflammation, and relieve hypo-perfusion symptoms.

Chemically defined ascaroside derivatives replace crude nematode factors to suppress IL-6 and IL-1β and improve control of autoimmune inflammation.

Targets MYT1 to disrupt the G2 checkpoint in p53-mutant tumor cells, improving selective cancer cell damage while limiting harm to normal cells.

Brain-penetrant sGC stimulators raise cGMP without NO dependence, addressing CNS treatment limits caused by poor blood-brain barrier crossing.

A modified polysaccharide replaces PEG in lipid particles to reduce allergenic risk while maintaining stability and drug delivery efficacy.

Protective RNA nanostructures improve nuclease resistance and targeting to tumor and immune cells for stronger mRNA therapy and immune activation.

Modified azalides separate anti-inflammatory immune modulation from antibacterial effects, helping treat animal respiratory inflammation while reducing resistance pressure.

A long-chain lipid A lipopolysaccharide shifts macrophages to M2 to support lung development and diaphragm repair in CDH.

Small molecule CD73 inhibitors lower tumor adenosine, restore immune cell function, and retain human hepatocyte stability in cancer treatment.

PROTAC degraders remove CDK12/13 proteins rather than only blocking kinase activity, helping overcome incomplete inhibition and resistance.

An alginate oral film with adrenaline and antioxidant enables needle-free delivery with stable plasma levels and room-temperature stability.

Subtype-selective M4 antagonists address the efficacy versus adverse-effect tradeoff in Parkinson's treatment by sparing other muscarinic receptors.

Salt forms of sepiapterin improve stability, purity, and exposure, helping raise tetrahydrobiopterin levels for PBD-related disorders.

Targeted deuteration of dronedarone preserves anti-atrial fibrillation activity while reducing ventricular proarrhythmic and organ toxicity.

Small-molecule pyridopyrimidine inhibitors block PD-1/PD-L1 while improving oral delivery, tumor penetration, and sustained tissue exposure.

Chemically modified double-stranded siRNA with conjugates improves HBsAg reduction in HBV while lowering off-target effects and safety risks.

Engineered CAR T cells use multi-antigen recognition and modular domains to limit antigen escape and improve remission durability.

A fixed oral testosterone undecanoate dose maintains safe, effective serum levels across patients without time-consuming titration.

Specific polymers keep a poorly soluble P2X4 antagonist amorphous, improving oral absorbability while preserving storage stability.

An oral blend of collagen peptides, hyaluronic acid, astragalus, and centella supports vaginal mucosa repair and lasting relief from dryness and itching.

A riluzole prodrug improves metabolic stability and dosing for SCA3 treatment while supporting better symptom management and study feasibility.

Bicyclic compounds tuned for RIP-1 kinase inhibition help suppress programmed necrosis and reduce systemic inflammatory responses.

Selective 6-alkoxypyrazolopyrimidine compounds inhibit NLRP3 inflammasomes to lower IL-1β and IL-18 in chronic inflammatory disease.

Low-pressure roller compaction and sieving create racecadotril granules with controlled size distribution for better dissolution and bioavailability.

Hydrochloride polymorphs turn non-crystalline Compound A into stable, soluble crystals suited to solid pharmaceutical dosage forms.

Novel pyrrolidine-fused myrtanol derivatives improve IDO1 inhibition and degradation specificity to modulate the kynurenine pathway.

Difructose anhydride III boosts intestinal IgA production during the suckling period, helping protect newborn animals from early infections.

Using tapentadol phosphate with a hydrophobic coating slows release in aqueous ethanol and helps prevent alcohol-induced dose dumping.

A pyranopyridine scaffold improves CYP11B2 selectivity to lower aldosterone while minimizing cortisol synthase inhibition and related side effects.

Selective BCL6 BTB-domain inhibitors block corepressor recruitment to curb malignant B cell proliferation despite synthesis complexity.

Using 2'-fucosyllactose, this case shows how GLS1 inhibition can remove senescent cells while supporting normal proliferation and skin matrix repair.

Using crude phytosterol directly avoids laborious sterol separation while improving yield and cost in 25-OH cholesterol and calcifediol synthesis.

A catechin-derived gut metabolite activates conventional dendritic cells to boost CD8+ cytotoxic immunity with fewer side effects.